Antiviral liponucleosides: treatment of hepatitis B
US6252060A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Apr 4, 1994 |
| Grant date | Jun 26, 2001 |
| Priority date | — |
| Expiry date | Apr 4, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/207
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds for treating hepatitis B infections. The compounds consist of nucleoside analogues having anti-hepatitis B activity which are linked, commonly through a 5' phosphate of the pentose residue, to one of a selected group of lipids. The lipophilic nature of these compounds provides an advantage over the use of the nucleoside analogue alone, making it possible to incorporate them into the lamellar structure of liposomes, either alone or in combination with similar lipid molecules. In the form of appropriately sized liposomes, these anti-hepatitis B agents are preferentially taken up by the liver cells which have been found to harbor the target virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.